Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Risk for endophthalmitis no higher with Avastin, finds study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Their findings are published today in JAMA Ophthalmology.

14 Aug 2015

Improved method for building proteins into antibodies

Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.

14 Aug 2015

TSRI-led team devises selection-based, protein-engineering method to work on obesity therapy

Some proteins exist so fleetingly in the bloodstream that they can’t be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute has devised an improved method for accomplishing this protein-engineering feat.

14 Aug 2015

Researchers help explain how malaria infection increases children's risk of developing Burkitt's lymphoma

In equatorial Africa, a region of the globe known as the "lymphoma belt," children are ten times more likely than in other parts of the world to develop Burkitt's lymphoma, a highly aggressive blood cancer that can be fatal if left untreated. That area is also plagued by high rates of malaria, and scientists have spent the last 50 years trying to understand how the two diseases are connected.

14 Aug 2015

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.

14 Aug 2015

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics, Inc. announces the launch of an observational clinical study in patients who contracted Progressive Multifocal Leukoencephalopathy (PML), the rare and often fatal brain infection that arises as an unintended side effect of some medications used for treatment of Multiple Sclerosis, Crohn's disease, Ulcerative Colitis and certain cancers of the blood and lymph.

13 Aug 2015

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.

12 Aug 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.

11 Aug 2015

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.

11 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.

10 Aug 2015

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Sorrento Therapeutics, Inc. announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies.

10 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group, one of India's leading generic pharmaceutical companies and one of the world's largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India.

5 Aug 2015

Researchers find CD163 protein limits muscle repair after ischemic injury

Researchers have identified a protein produced by white blood cells that puts the brakes on muscle repair after injury. By removing the protein CD163 from mice, scientists at Emory University School of Medicine could boost muscle repair and recovery of blood flow after ischemic injury (damage caused by restriction of blood flow).

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

5 Aug 2015

G7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting GPCRs and ion channels

MorphoSys AG and G7 Therapeutics AG announced today that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors and potentially other disease-related transmembrane proteins such as ion channels.

4 Aug 2015

Penn Medicine devises new approach to develop vaccines against lethal diseases

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination.

4 Aug 2015

Antibody News and Research

Further Reading

Risk for endophthalmitis no higher with Avastin, finds study

Improved method for building proteins into antibodies

TSRI-led team devises selection-based, protein-engineering method to work on obesity therapy

Researchers help explain how malaria infection increases children's risk of developing Burkitt's lymphoma

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Researchers find CD163 protein limits muscle repair after ischemic injury

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

G7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting GPCRs and ion channels

Penn Medicine devises new approach to develop vaccines against lethal diseases

Event guide: Targeted Therapies Partnering & Licensing Summit Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo